- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00004029
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
I. Assess the toxicity associated with repeated vaccination with recombinant vaccinia virus expressing prostate-specific antigen (rV-PSA) in patients with metastatic adenocarcinoma of the prostate.
II. Determine the optimal dose of rV-PSA given at monthly intervals based on cellular and hormonal immunity.
III. Determine whether vaccination with rV-PSA is associated with anti-tumor activity.
IV. Determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) has an effect on cellular and humoral immunity different from rV-PSA, and whether the addition of GM-CSF has enhanced antitumor effect compared to rV-PSA alone.
OUTLINE: This is an open label, dose escalation study.
Patients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
Patients are followed monthly for 6 months.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Förenta staterna, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma of the prostate with evidence of metastatic disease based on any of the following:
- Lymph node positive and PSA at least 10 ng/mL
- Bone scan positive and PSA at least 10 ng/mL
- PSA at least 2 ng/mL and rising following radical prostatectomy
- PSA at least 10 ng/mL following radiotherapy
- No symptomatic metastatic disease (bony pain)
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: ECOG 0 or 1
- WBC greater than 2,000/mm3
- Platelet count greater than 100,000/mm3
- Bilirubin less than 2.0 mg/dL
- AST less than 4 times normal
- Creatinine less than 2.0 mg/dL
- Must be type HLA-A2 Prior vaccinia (smallpox) exposure required
- At least normal delayed type hypersensitivity to mumps and Candida
- At least normal CD4:CD8 ratio (greater than 1)
- At least normal lymphocyte proliferation testing (to Con A)
- At least normal immunoglobulin levels
- No evidence of altered immune responsiveness or autoimmune syndromes (e.g., scleroderma, systemic lupus erythematosus)
- No HIV antibody No prior splenectomy
- No known allergy to eggs
- No active extensive skin disorders (e.g, psoriasis, burns, impetigo, disseminated zoster)
- No other serious intercurrent illness
- No active infections unless cleared and at least 3 days since antibiotic therapy
No close contact for 2 weeks after each vaccination with the following people:
- Children less than 3 years old
- Pregnant women
- Individuals with eczema or skin conditions listed above
- Immunosuppressed individuals
PRIOR CONCURRENT THERAPY:
- No concurrent biologic therapy
- No prior chemotherapy for metastatic disease
- No prior hormone therapy for metastatic disease
- Neoadjuvant hormone therapy prior to prostatectomy or radiotherapy allowed
- No concurrent steroids or hormonal medications
- Prior radiotherapy allowed
- Prior surgery allowed
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm I
atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity.
Response assessment is performed at eight weeks.
Patients who discontinue therapy prior to eight weeks are considered unevaluable for response.
If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level.
Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle.
Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1692, 439, 1999.
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1672, 434, 1998.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000065275
- DFCI-96079
- NCI-T95-0086H
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på sargramostim
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Avslutad
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Avslutad
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AvslutadMetastaserande cancer | Melanom (hud)Förenta staterna
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AvslutadNjurcancer | Metastaserande cancerFörenta staterna, Kanada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)Okänd
-
Roswell Park Cancer InstituteAvslutadLymfom | Myelodysplastiska syndrom | Leukemi | Kroniska myeloproliferativa störningar | Graft kontra värdsjukdom | Myelodysplastiska/myeloproliferativa neoplasmerFörenta staterna
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AvslutadMetastaserande cancer | Melanom (hud)Förenta staterna
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)AvslutadSargramostim efter benmärgstransplantation vid behandling av patienter med myelodysplastiskt syndromMyelodysplastiska syndrom | Leukemi | Myelodysplastiska/myeloproliferativa sjukdomarFörenta staterna
-
Milton S. Hershey Medical CenterIndragenLunginflammation | Akut respiratoriskt distress-syndrom | Luftvägsvirusinfektion
-
SanofiIndragen